Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects.
Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects.
复制标题
蛋白质翻译和核蛋白输出的双重靶向可增强抗骨髓瘤效果。
DOI:
10.1182/bloodadvances.2021006638
复制
发表时间:
2023-06-27
期刊:
影响因子:
7.5
通讯作者:
Lentzsch, Suzanne
中科院分区:
文献类型:
--
作者:
Li, Shirong;Fu, Jing;Walker, Christopher J.;Yang, Jun;Bhutani, Divaya;Chakraborty, Rajshekhar;Mamillapalli, Niha;Mapara, Markus Y.;Landesman, Yosef;Lentzsch, Suzanne
Knockdown of eIF4E sensitizes resistant MM cell lines to selinexor. These data provide a rationale for further evaluating the combination of selinexor and elF4E inhibitors in MM. Selinexor (KPT-330) is a small molecule inhibitor of XPO1, which mediates the transport of tumor suppressor proteins, oncogene messenger RNAs, and other proteins involved in governing cell growthfrom the cell nucleus to the cytoplasm. It is overexpressed in many cancer types. Because eukaryotic translation initiator factor 4E (eIF4E) plays a critical role in protein translation in cancer cells in multiple myeloma (MM), we evaluated the effectiveness of combined inhibition of protein translation and nuclear export in MM. Selinexor, an inhibitor of nuclear protein export, dose-dependently decreased eIF4E, IKZF1, and c-MYC protein levels. Using a doxycycline-inducible–pLKO-Tet-On vector, knockdown of eIF4E significantly enhanced the antiproliferative effects of selinexor, sensitized resistant MM cells to selinexor, and increased apoptosis in MM cells. Immunofluorescent analysis of MM cells showed that the combined treatment increased the localization of residual eIF4E to the nucleus compared with selinexor-only treatment. The overexpression of eIF4E at least partially rescued the effects of selinexor in MM cells by reducing G1 cell cycle arrest and increasing the selinexor-IC50 10-fold. Moreover, the combination of selinexor with pharmacologic inhibitors of protein translation showed synergistic anti-MM effects. These results suggest a synergistic anti-MM effect of selinexor combined with eIF4E inhibitors in vitro. Our work provides a better understanding of the potential mechanism of resistance to selinexor and a rationale for combining selinexor with eIF4E inhibitors for the treatment of MM.
登录
查看更多内容
DOI:
10.1016/j.bbrc.2008.07.163
发表时间:
2008-10-24
影响因子:
3.1
作者:
Tan, Keith;Culjkovic, Bijana;Amri, Abdellatif;Borden, Katherine L. B.
通讯作者:
Borden, Katherine L. B.
影响因子:
8.8
作者:
Culjkovic-Kraljacic B;Baguet A;Volpon L;Amri A;Borden KL
通讯作者:
Borden KL
影响因子:
5
作者:
Attar-Schneider, Oshrat;Drucker, Liat;Lishner, Michael
通讯作者:
Lishner, Michael
DOI:
10.1158/1078-0432.ccr-10-0433
发表时间:
2010-10-15
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
Hsieh AC;Ruggero D
通讯作者:
Ruggero D
影响因子:
81.5
作者:
Kumar, Shaji K.;Rajkumar, Vincent;Anderson, Kenneth C.
通讯作者:
Anderson, Kenneth C.